Background: Recent clinical trials have shown that immune-checkpoint blockade yields a clinical response in a subset of individuals with advanced nonsmall-cell lung cancer (NSCLC). We examined whether the expression of programmed death-ligand 1 (PD-L1) is related to clinicopathologic or prognostic factors in patients with surgically resected NSCLC.
introduction
Lung cancer is the leading cause of cancer death worldwide [1] . Recent advances in targeted therapy, however, have led to a major paradigm shift in clinical oncology. Molecularly targeted drugs such as erlotinib and crizotinib have thus greatly improved the clinical course for nonsmall-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) gene translocations, respectively. Despite these advances, however, the prognosis of individuals with NSCLC who do not harbor an identifiable driver oncogene remains poor [2] .
Blockade of immune checkpoints with monoclonal antibodies has also recently emerged as a new therapeutic tool in oncology [3] . Programmed death 1 (PD1), which belongs to the CD28 family of proteins, is a receptor expressed on the surface of T cells that regulates their activation and proliferation. Its ligand, programmed death-ligand 1 (PD-L1), is frequently overexpressed in many types of human cancer [3] . The binding of PD-L1 to PD1 induces apoptosis or exhaustion in activated T cells, and blockade of this interaction has been shown to enhance the antitumor activity of T cells [3] . Recent clinical trials found that inhibition of the PD-L1-PD1 interaction with antibodies specific for these proteins had promising antitumor efficacy in patients with various malignancies including NSCLC [4, 5] . The clinical relevance of PD-L1 expression in NSCLC has remained unclear, however. We have therefore now examined PD-L1 expression in surgically resected NSCLC specimens and analyzed its associated clinicopathologic characteristics and prognostic relevance.
materials and methods cell culture and reagents
Human NSCLC cell lines were maintained under a humidified atmosphere of 5% CO 2 at 37°C in RPMI 1640 medium (PC9, HCC827, NCI-H1975, QG56, 1-87, H1299, H2122, H322, H460, LK2, LK87, H23) or in Dulbecco's modified eagle's medium (A549, H157), each supplemented with 10% fetal bovine serum. Both HCC827 and PC9 cell lines harbor an activating inframe deletion [del(E746-A750)] in exon 19 of EGFR; H1975 harbors an activating mutation (L858R) in exon 21 as well as a secondary mutation (T790M) in exon 20 that contributes to the development of resistance to EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib; and all other cell lines are wild type for EGFR [6] (supplementary Data 1, available at Annals of Oncology online). Erlotinib was obtained from Cayman Chemical (Ann Arbor, MI).
patients and EGFR mutation analysis
In this retrospective study, we screened 164 NSCLC patients who underwent surgical resection of their tumors between 2000 and 2010 at Kurume University Hospital. EGFR mutations were identified in tumor tissue by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method [7] . The present study conforms to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Kurume University Hospital.
immunohistochemical analysis of PD-L1 expression in tumor specimens
Paraffin-embedded tumor tissue was sectioned at a thickness of 4 µm, and the sections were then mounted on glass slides for immunohistochemical analysis of PD-L1 with the use of the BenchMark XT platform (Ventana Automated Systems, Tucson, AZ). In brief, each slide was subjected to heat treatment in Ventana CC1 retrieval solution for 30 min and then incubated for 30 min with rabbit polyclonal antibodies to human PD-L1 (Lifespan Biosciences, Seattle, WA). Immune complexes were detected with the use of an ultraVIEW 3,3 0 -diaminobenzidine (DAB) detection kit with DAB as the chromogen (Ventana). The intensity of staining was evaluated according to the following scale: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The proportion of all tumor cells found to express PD-L1 was determined and then multiplied by the staining intensity score to obtain a final semiquantitative H score (maximum value of 300 corresponding to 100% of tumor cells positive for PD-L1 with an overall staining intensity score of 3). All immunohistochemical images were evaluated by two experienced observers (AK and MK) who were unaware of the identity of the specimens, and the mean of the two determinations was used for further analysis.
analysis of PD-L1 expression and EGFR phosphorylation in NSCLC cell lines
To examine the effect of EGFR signaling on PD-L1 expression, we exposed PC9, HCC827, H1975, or A549 cells to 100 nM erlotinib for 48 h and then stained the cells consecutively with biotinylated mouse monoclonal antibodies to human PD-L1 (eBioscience, San Diego, CA) and phycoerythrinlabeled streptavidin (BD Biosciences, San Jose, CA) for flow cytometric analysis with a FACS Calibur instrument equipped with CELLQuest software (BD Biosciences) [8] . For examination of EGFR phosphorylation, immunoblot analysis was carried out as previously described [9] with rabbit polyclonal antibodies to phosphorylated ( pY1086) or total forms of EGFR (Cell Signaling Technology, Danvers, MA).
statistical analysis
See supplementary Data 2, available at Annals of Oncology online.
results

patient characteristics
A total of 164 patients with NSCLC (114 with adenocarcinoma and 50 with squamous cell carcinoma) who underwent surgical resection was included in the present study (Table 1) . Ninetyone (55%) patients were male and 95 (58%) were never smokers, and the median age of all patients was 66 years (range, 39-82 years). With regard to EGFR mutation status, 30 patients harbored a deletion in exon 19 and 27 patients had an L858R missense mutation in exon 21.
immunohistochemical analysis of PD-L1 expression in tumor specimens
Immunohistochemical staining for PD-L1 was detected at the membrane or in the cytoplasm (or both) of tumor cells and stromal lymphocytes in the surgically resected tumor specimens ( Figure 1A ). Expression of PD-L1 was significantly higher in tumors from women than in those from men (P < 0.001), in those with an adenocarcinoma histology than in those with a squamous cell carcinoma histology (P < 0.001), in those from never smokers than in those from smokers (P < 0.001), and in those positive for EGFR mutations than in those wild type for EGFR (P < 0.001) ( Figure 1B ). No significant association was detected between expression of PD-L1 and either patient age (≤66 versus >66 years, P = 0.228) or tumor p stage (I versus II or III, P = 0.207). Given that EGFR mutations are more frequently found in women, never smokers, and individuals with adenocarcinoma [2] , we carried out multivariate analysis to examine which factors were associated with expression of PD-L1 in the present study. Multivariate analysis revealed that EGFR mutation positivity and adenocarcinoma histology were associated with high expression of PD-L1 independently of other patient characteristics (P = 0.027 and P = 0.046, respectively) ( Table 2) .
regulation of PD-L1 expression by EGFR signaling in EGFR mutation-positive NSCLC cells
Given the positive association between EGFR mutation and high PD-L1 expression in NSCLC tumors, we examined the expression of PD-L1 in NSCLC cell lines whose EGFR mutation status had been previously determined. Three (HCC827, PC9, and H1975) of the 14 cell lines examined harbor EGFR mutations, whereas the other 11 cell lines are wild type for EGFR. Both HCC827 and PC9 harbor an activating in-frame deletion in exon 19 of EGFR, whereas H1975 harbors an activating L858R mutation in exon 21 as well as a secondary mutation (T790M) in exon 20 that contributes to the development of resistance to EGFR-TKIs such as gefitinib and erlotinib. Flow cytometric analysis revealed that the level of PD-L1 expression at the cell surface was significantly higher for cell lines with EGFR mutations than for those with wild-type EGFR (P = 0.023) (Figure 2A ). To examine the role of oncogenic EGFR signaling in the regulation of PD-L1 expression, we determined the effect of the EGFR-TKI erlotinib on PD-L1 abundance in NSCLC cell lines. Consistent with our previous observations, immunoblot analysis revealed that EGFR phosphorylation was undetectable in EGFR mutation-negative A549 cells [9] , whereas EGFR mutation-positive PC9, HCC827, and H1975 cells manifested a high basal level of EGFR phosphorylation ( Figure 2B ). Treatment of PC9 and HCC827 cells with erlotinib resulted in marked downregulation of PD-L1 expression at the cell surface ( Figure 2C ) as well as inhibition of EGFR phosphorylation ( Figure 2B ), whereas erlotinib did not affect PD-L1 expression or EGFR phosphorylation in A549 cells. The T790M mutation impedes the binding of gefitinib and erlotinib to the ATP binding pocket of the catalytic domain of EGFR. Importantly, erlotinib had no effect not only on EGFR phosphorylation but also on PD-L1 expression in H1975 cells, which harbor both L858R and T790M mutations ( Figure 2B and C) . Together, these data thus suggested that the expression of PD-L1 is upregulated by EGFR signaling in EGFR mutation-positive NSCLC cells.
survival analysis in NSCLC patients
The median follow-up time for all 164 patients was 55.6 months (range, 0.8-168.4 months). NSCLC patients with a high expression score for PD-L1 had a significantly shorter OS compared with those with a low expression score (median of 55.9 versus 72.6 months, P = 0.039) (Figure 3 ). Univariate analysis revealed that, among the characteristics examined, only the expression score for PD-L1 (P = 0.039) and p stage (P < 0.001) were significantly associated with OS (Table 3) . Cox regression analysis also revealed that high PD-L1 expression (P = 0.020) and p stage II or III (P < 0.001) were significantly associated with a shorter OS independently of other factors (Table 3) .
discussion Therapeutic strategies that target the PD1-PD-L1 axis have yielded objective responses in a subset of individuals with advanced NSCLC in early-phase clinical trials. Preliminary results suggest that PD-L1 expression in tumors is correlated with a higher likelihood of response to PD1-targeted antibodies [3] . Although several studies have examined PD-L1 expression in NSCLC [4, 5] , the clinicopathologic characteristics associated with PD-L1 expression in such tumors have remained largely unknown. Expression of PD-L1 was recently found to be increased in EGFR-driven murine lung tumors, with this increased expression contributing to escape from the antitumor immune response [10] . We have now examined PD-L1 expression by immunohistochemistry in 164 surgically resected specimens of NSCLC. The data from our Japanese cohort revealed higher PD-L1 expression in women than in men, in never smokers than in smokers, and in individuals with adenocarcinoma than in those with squamous cell carcinoma, which also correspond to the subsets of patients who are more likely to harbor EGFR mutations. Multivariate analysis revealed that the presence of EGFR mutations and adenocarcinoma histology were also significantly associated with increased PD-L1 expression independently of other factors. The relatively high prevalence of EGFR mutations in the Japanese population may have facilitated the detection of this association [2, 9] . Consistent with the positive association between EGFR mutations and increased PD-L1 expression in completely resected NSCLC tissue, we also found that the expression level of PD-L1 Low PD-L1 High PD-L1 Figure 3 . Kaplan-Meier analysis of OS according to PD-L1 expression score in NSCLC patients. The median value (30) of all H scores was a priori chosen as the cutoff point for separating tumors with high or low PD-L1 expression. The P value for the difference between the two curves was determined by the log-rank test. Treatment with a PD1-specific antibody was also found to inhibit tumor growth and to improve survival in mice bearing EGFR-dependent lung tumors [10] . These data suggest that therapeutic blockade of the PD1-PD-L1 pathway may enhance the efficacy of treatment of EGFR mutation-positive NSCLC. Furthermore, in addition to inhibition of tumor growth and tumor survival dependent on EGFR signaling, downregulation of PD-L1 expression and consequent activation of an antitumor immune response also may contribute to the durable therapeutic response of EGFR mutation-positive NSCLC patients to EGFR-TKIs. The secondary mutation T790M of EGFR has been detected in up to 60% of NSCLC tumors with acquired resistance to EGFR-TKIs [6] . We have now found that EGFR-TKI-resistant H1975 cells, which harbor both an activating mutation and T790M in EGFR, continue to express PD-L1 at a high level even in the presence of erlotinib, suggesting that blockade of PD1-PD-L1 signaling is a potential approach to help overcome acquired resistance to EGFR-TKIs in EGFR mutation-positive NSCLC. We found that patients with a high expression score for PD-L1 had a significantly poorer survival outcome compared with those with a low expression score. Multivariate analysis revealed that high expression of PD-L1 and advanced stage were significantly associated with poor prognosis independently of the other factors examined. These results are consistent with previous studies showing that high expression of PD-L1 is associated with poor prognosis in several human malignancies [3, [11] [12] [13] , suggesting that high expression of PD-L1 on tumor cells promotes tumor recurrence by interrupting antitumor immunity [3] . Indeed, we observed that patients with a high expression score for PD-L1 had a significantly higher rate of recurrent disease than did those with a low expression score (79% versus 50%, P < 0.0001). We also analyzed survival rate and recurrence rate at each year after surgery for the NSCLC patients in the present study (supplementary Tables S1 and S2, available at Annals of Oncology online). The survival rates according to PD-L1 expression score differed significantly at ≥6 years after tumor resection but not before. This delayed separation of the survival curves according to PD-L1 expression is consistent with the late curve divergence repeatedly observed in successful immunotherapy trials [14] . This long latent period may reflect the time required for tumor cells with a high level of PD-L1 expression to relapse through escape from antitumor immunity. Although our study is retrospective in nature and has a relatively small sample size, our results provide a rationale for future clinical investigations of the PD1-PD-L1 axis as a target for adjuvant chemotherapy in individuals with NSCLC whose resected tumors are found to have a high expression score for PD-L1.
Given that we measured PD-L1 expression in operable NSCLC patients at p stages I-III, it remains unclear whether our findings will also be applicable to patients with stage IV disease.
Furthermore, although our semiquantitative immunohistochemical method for analysis of PD-L1 expression is widely accessible, PD-L1 expression in tumor cells has been evaluated with various antibodies and conditions [11] [12] [13] . For future clinical applications, further efforts to standardize a quantitative assay for PD-L1 expression are warranted.
In conclusion, high expression of PD-L1 in resected tumors was found to be positively associated with the presence of EGFR mutations and to be an independent negative prognostic factor in NSCLC patients. Further studies are warranted to clarify the molecular mechanisms responsible for regulation of PD-L1 expression in EGFR mutation-positive NSCLC. 
